Open AccessATYPICAL HEMOLYTIC-UREMIC SYNDROME DURING PREGNANCY. PRESENT AND LATEST RESULTS OF TREATMENT
Author(s) -
Н.А. Жаркин,
М. Е. Стаценко,
M.M. Stazharova,
Н.А. Бурова,
S.A. Prokhvatilov
Publication year - 2019
Publication title -
arhiv akušerstva i ginekologii im. v.f. snegireva
Language(s) - English
Resource type - Journals
eISSN - 2687-1386
pISSN - 2313-8726
DOI - 10.18821/2313-8726-2019-6-1-47-50
Subject(s) - eculizumab , medicine , thrombotic microangiopathy , pregnancy , atypical hemolytic uremic syndrome , coagulation , thrombosis , complement system , immunology , intensive care medicine , disease , antibody , biology , genetics
Atypical hemolytic-uremic syndrome being referred to autoimmune diseases appears to be one of the most severe forms of thrombosis and microangiopathy. Difficulties in diagnosis cause a delay in pathogenetic therapy, which causes a high maternal mortality rate. Pathogenetic therapy with eculizumab, suppressing the terminal activity of complement, may contribute to the recovery of blood coagulation properties, but the long-term prognosis for chronic renal failure remains unfavorable. The article deals with a clinical case confirming this conclusion.